Abstract
Objectives: Paraoxonase-1 (PON1) is an enzyme that degrades lipid peroxides and reduces oxidative stress. Previous studies showed a low PON1 activity in patients with non-alcoholic fatty liver disease (NAFLD). Metformin is used as an anti-diabetic drug and ameliorates insulin resistance by improving insulin sensitivity in liver. The aim of this study was to evaluate the effects of metformin in PON1-deficient mice, which have hepatic steatosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
